FDA Approves Once-Weekly Product for Hemophilia A

France Nouvelles Nouvelles

FDA Approves Once-Weekly Product for Hemophilia A
France Dernières Nouvelles,France Actualités
  • 📰 Medscape
  • ⏱ Reading Time:
  • 50 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 23%
  • Publisher: 55%

FDA has approved efanesoctocog alfa, a first-in-class, high-sustained factor VIII replacement therapy for adults and children over 12 years old with hemophilia A.

The US Food and Drug Administration has approved efanesoctocog alfa , a first-in-class, high-sustained factor VIII replacement therapy for adults and children over 12 years old with hemophilia A.

The product is used once a week and is indicated for routine prophylaxis and on-demand treatment to control bleeding episodes, as well as to control bleeding during surgery .is “the first and only hemophilia A treatment that delivers normal to near-normal factor activity levels for most of the week with once-weekly dosing, and significantly reduces bleeds compared to prior factor VIII prophylaxis.

With this product,"we have the opportunity to provide near normal factor activity levels for an extended period of time with a single dose, which is a first for hemophilia A," Angela Weyand, MD, of Michigan Medicine,who was involved in the pivotal phase 3 XTEND-1 trial that led to approval.. The results show that one injection of efanesoctocog alfa, a factor VIII therapy, resolved almost all bleeding episodes in the overall patient population and weekly prophylaxis provided mean factor VIII activity in the normal or near-normal range for most of the week, as

Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite:

Medscape /  🏆 386. in US

France Dernières Nouvelles, France Actualités

Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.

U.S. FDA approves Sanofi's bleeding disorder therapyU.S. FDA approves Sanofi's bleeding disorder therapyU.S. health regulators have approved Sanofi SA's therapy to treat a type of inherited bleeding disorder known as hemophilia A, the French drugmaker said on Thursday, and expects to launch it in the United States in April.
Lire la suite »

With Pappas likely leaving Hobby Airport, new restaurants could include Killen's, Velvet TacoWith Pappas likely leaving Hobby Airport, new restaurants could include Killen's, Velvet TacoIf Houston City Council approves a contract on the agenda this month, these 10 restaurants would replace the Pappas concepts over the next two years, including Killen's BBQ and The Spot.
Lire la suite »

FDA Broadens Warning on Potentially Contaminated Eye ProductsFDA Broadens Warning on Potentially Contaminated Eye Products🚫 Do not purchase or use Delsam Pharma’s Artificial Eye Ointment, the FDA warns.
Lire la suite »

FDA agrees to review Pfizer's RSV vaccine for pregnant individualsFDA agrees to review Pfizer's RSV vaccine for pregnant individualsThe Food and Drug Administration has accepted an application from Pfizer to review its RSV vaccine for pregnant individuals.
Lire la suite »

FDA expands warning about potentially contaminated eye products amid outbreakFDA expands warning about potentially contaminated eye products amid outbreakThe FDA warned of another imported eye product that could be contaminated with bacteria, in the wake of an outbreak earlier this year of highly drug-resistant bacteria that hospitalized and blinded some patients.
Lire la suite »

Anchorage Assembly approves ‘online checkbook’ to make public finances more transparentAnchorage Assembly approves ‘online checkbook’ to make public finances more transparentThe Anchorage Assembly on Tuesday directed the city to establish an “online checkbook” that would make it easier for residents to see how the municipality is spending public money.
Lire la suite »



Render Time: 2025-03-01 14:52:37